$268 Billion in U.S. Life Science Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $268 billion invested to drive new R&D, expand manufacturing and create jobs nationwide.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, with millions of high-skill positions for scientists and engineers, alongside tens of thousands of construction and support roles and millions of jobs for the communities surrounding these cutting edge faciltiies. This includes more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
766%
increase in facility investment announcements versus 2024
10K+
new construction jobs across America
The biopharmaceutical industry’s investments reflect a commitment to ensuring the U.S. remains a leader in the life sciences, but China continues a coordinated campaign to dominate the life sciences, jeopardizing America’s momentum.
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
Faster delivery
of breakthrough medicines to patients
U.S. Life Sciences Investment Tracker:
July 21, 2025
Biogen
$2 billion
Wake County-NC, Durham County-NC
With a manufacturing expansion and modernization in the Research Triangle, Biogen looks to enhance its capabilities for gene-targeted therapies – expanding antisense oligonucleotide production and adding new multi-platform fill-finish capacity at both clinical and commercial scales. Advanced automation and AI-driven process controls are part of the upgrades.
May 14, 2025
Sanofi
$20 billion
Unspecified location
Substantially increasing spending on U.S. R&D. Sanofi also announced plans to expand U.S. manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers, to help ensure the production of medicines in the U.S.
May 12, 2025
Roche
$550 million
Indianapolis-IN
Expanding its campus into a major hub for manufacturing continuous glucose monitoring (CGM) systems for diabetes management and adding a new diagnostics production facility.
The expansion is expected to create “hundreds” of skilled manufacturing jobs and thousands of construction jobs in Indiana.
May 12, 2025
Roche
$700 million
Holly Springs-NC
The first East Coast manufacturing site for Genentech (Roche’s U.S. subsidiary) is a fill-finish biologics plant that will produce metabolic medicines, including next-gen obesity treatments, to support growing demand.
The project is part of Roche’s $50B U.S. initiative and will create more than 400 local full-time jobs when operational (2029) and about 1,500 construction jobs during development.
No entries found matching your criteria. Please modify your filters.